What the FDA labels say about taking them together
Meloxicam and pemetrexed
Meloxicam's FDA label (Qamzova) of July 16, 2026 names pemetrexed in its drug interactions section; the pemetrexed labels PlainMeds reads (4) do not name meloxicam. The meloxicam label: “Concomitant use of XIFYRM and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.); the pemetrexed FDA label on DailyMed (effective October 8, 2025, Avyxa Pharma, LLC).
What does the meloxicam label say about pemetrexed?
Qamzova label (Nanjing Delova Biotech Co., Ltd., July 16, 2026), drug interactionsPemetrexed Clinical Impact: Concomitant use of QAMZOVA and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). Intervention: During concomitant use of QAMZOVA and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. …
Source: FDA drug label (Qamzova, NDA217593), Nanjing Delova Biotech Co., Ltd., effective July 16, 2026 (SPL set 385fd779-1be1-49ae-8213-750b96ecc997), via openFDA
Source: FDA drug label (Xifyrm, NDA218395), Azurity Pharmaceuticals, Inc., effective June 18, 2025 (SPL set bf2b198c-0726-488a-b911-4fe394e4b56e), via openFDA
Source: FDA drug label (Meloxicam, NDA021530), Emerald Therapeutics, LLC, effective May 29, 2026 (SPL set 55af77dd-2abc-49a6-990c-399d5a5e7a91), via openFDA
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
What does the pemetrexed label say about meloxicam?
Pemetrexed's label (effective October 8, 2025) and its 3 other brand-application labels do not name meloxicam in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AXTLE), Avyxa Pharma, LLC, effective October 8, 2025 (SPL set 9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Meloxicam | Pemetrexed | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain | Lung cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0166 per tablet 7.5 mg tablet | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once